#Sweden #Stockholm #Sobi #Swedish Orphan Biovitrum #class C shares

Sobi Successfully Completes Class C Share Issues

On August 21, 2025, Swedish Orphan Biovitrum AB (publ), commonly known as Sobi®, announced a significant step in enhancing its operational framework by successfully executing issues of Class C shares. This decision was determined during the Annual General Meeting held on May 8, 2025, and is part of Sobi's strategy to secure its obligations under existing long-term incentive programs which are pivotal to its employee engagement and retention strategies.

Share Issues and Repurchase Plan

The resolution from the AGM authorized the Board of Directors to enact a repurchase of all issued Class C shares through a directed acquisition offer to all Class C shareholders of Sobi. This move aims to consolidate equity and provide an opportunity for shareholders to liquidate their holdings should they choose.

On July 15, 2025, the Board resolved, conditional upon the subscription and payment by Svenska Handelsbanken AB, to repurchase all 1,412,788 issued Class C shares. Following this resolution, Svenska Handelsbanken AB successfully subscribed for the entirety of the issued shares, leading to the completion of new share issues which totaled SEK 775,204.50.

The repurchase of these Class C shares is a significant decision as it impacts Sobi's capital structure and can potentially lead to future innovations or growth strategies as the company aims to improve value for its shareholders.

Strategic Conversion of Shares

Following the repurchase, there is an intention to convert the acquired Class C shares into common shares as per the conversion provision stipulated in Sobi’s articles of association. This conversion is strategically planned to ensure Sobi can deliver common shares to participants in its incentive programs, thereby aligning company performance with personal incentives of its workforce and thereby enhancing productivity and commitment.

Before the repurchase, Sobi held 11,343,749 of its common shares and currently holds none of its Class C shares after the completion. Upon the successful conversion, the total number of common shares held by Sobi will rise to 12,756,537.

About Sobi

Sobi is a global biopharmaceutical company that is committed to unlocking the potential of breakthroughs aimed at improving the lives of patients with rare diseases. Founded with a mission to transform everyday life for people facing challenging health conditions, Sobi has emerged as a leader in the sector. With about 1,900 employees across regions including Europe, North America, Asia, and Australia, Sobi has recorded a revenue of SEK 26 billion in 2024.

The company’s shares are traded on the Nasdaq Stockholm exchange under the ticker symbol STO SOBI. Sobi continues to focus on enhancing its portfolio and exploring opportunities in innovative treatments. More detailed information regarding Sobi and its ongoing projects can be accessed via their official website and social media channels.

Conclusion

With the completion of the issues of Class C shares, Sobi positions itself to better manage its incentives and fulfill its obligations efficiently. This strategic move not only reassures investors but sets a robust framework for future expansions and innovations. As the landscape of biopharmaceuticals continues evolving, Sobi's firm footing could play a pivotal role in addressing the needs of patients with rare conditions and fostering transformative medical innovations.